{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:21:26Z","timestamp":1783052486214,"version":"3.54.6"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030622","name":"UNC Department of Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007137","name":"Texas Children's Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007137","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015581","name":"Houston Methodist Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018785","name":"Sophisticated Analytical Instrument Facility","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["R01CA257563"],"award-info":[{"award-number":["R01CA257563"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.115004","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:54:28Z","timestamp":1778601268000},"page":"115004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Biodegradable nanofibrous drug-eluting seed for sustained intratumoral immunotherapy"],"prefix":"10.1016","volume":"395","author":[{"given":"Francesco","family":"Manfredi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin Vander","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Di Trani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Maria","family":"Paci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Settis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison Alexandra","family":"Deeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Badachhape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxman","family":"Devkota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elsayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinh Chuong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simbarashe","family":"Jokonya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Stayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine Ying Xuan","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Grattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.jconrel.2026.115004_bb0005","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.3390\/jcm13216537","article-title":"Next-generation immunotherapy: advancing clinical applications in cancer treatment","volume":"13","author":"Garg","year":"2024","journal-title":"J. Clin. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115004_bb0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115004_bb0015","article-title":"Emerging technologies for local cancer treatment","volume":"3","author":"Chua","year":"2020","journal-title":"Adv. Ther."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115004_bb0020","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nrc.2017.93","article-title":"Transport of drugs from blood vessels to tumour tissue","volume":"17","author":"Dewhirst","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115004_bb0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","article-title":"Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside","volume":"4","author":"Stylianopoulos","year":"2018","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115004_bb0030","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.trecan.2018.02.008","article-title":"Transport barriers and oncophysics in cancer treatment","volume":"4","author":"Nizzero","year":"2018","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115004_bb0035","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13181-021-00833-8","article-title":"A review of cancer immunotherapy toxicity: immune checkpoint inhibitors","volume":"17","author":"Chhabra","year":"2021","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.jconrel.2026.115004_bb0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"28","key":"10.1016\/j.jconrel.2026.115004_bb0045","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with Ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115004_bb0050","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.jconrel.2026.115004_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1479483","article-title":"Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer","volume":"15","author":"Skalickova","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.115004_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1385484","article-title":"Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies","volume":"15","author":"Mantooth","year":"2024","journal-title":"Front. Immunol."},{"issue":"suppl_12","key":"10.1016\/j.jconrel.2026.115004_bb0065","doi-asserted-by":"crossref","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2026.115004_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114505","article-title":"Image-guided intratumoral immunotherapy: developing a clinically practical technology","volume":"189","author":"Som","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115004_bb0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.7911","article-title":"Assessment of image-guided intratumoral delivery of Immunotherapeutics in patients with cancer","volume":"3","author":"Sheth","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jconrel.2026.115004_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.601626","article-title":"Biodegradable polymeric nanoparticles for drug delivery to solid tumors","volume":"12","author":"Gagliardi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.115004_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2024.1336717","article-title":"Commercial hydrogel product for drug delivery based on route of administration","volume":"12","author":"Raeisi","year":"2024","journal-title":"Front. Chem."},{"issue":"20","key":"10.1016\/j.jconrel.2026.115004_bb0090","doi-asserted-by":"crossref","first-page":"19810","DOI":"10.1021\/acsnano.3c04037","article-title":"Meta-analysis of nanoparticle distribution in tumors and major organs in tumor-bearing mice","volume":"17","author":"Chen","year":"2023","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115004_bb0095","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molmed.2010.08.001","article-title":"Small-molecule delivery by nanoparticles for anticancer therapy","volume":"16","author":"Chen","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.jconrel.2026.115004_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113761","article-title":"An injectable hydrogel enhances intratumoral retention and antitumor efficacy of cytokine immunotherapy in murine triple negative breast tumor models","volume":"383","author":"Mantooth","year":"2025","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115004_bb0105","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1166\/jbn.2016.2288","article-title":"Nanochannel implants for minimally-invasive insertion and intratumoral delivery","volume":"12","author":"Hood","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115004_bb0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2018.06.035","article-title":"Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer","volume":"285","author":"Chua","year":"2018","journal-title":"J. Control. Release"},{"issue":"8_suppl","key":"10.1016\/j.jconrel.2026.115004_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/JCO.2019.37.8_suppl.37","article-title":"Localizing radioimmunotherapy via nanochannel device for sustained intratumoral drug delivery for solid tumor treatment","volume":"37","author":"Ho","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115004_bb0120","article-title":"Intratumoral nanofluidic system for enhancing tumor biodistribution of agonist CD40 antibody","volume":"3","author":"Chua","year":"2020","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115004_bb0125","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijrobp.2020.07.2326","article-title":"Potentiating antitumor efficacy through radiation and sustained intratumoral delivery of anti-CD40 and anti-PDL1","volume":"110","author":"Liu","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115004_bb0130","article-title":"Sustained Intratumoral Administration of Agonist CD40 antibody overcomes immunosuppressive tumor microenvironment in pancreatic cancer","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci. Weinh. Baden-Wurtt. Ger."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115004_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10594","article-title":"Intratumoral nanofluidic system enhanced tumor biodistribution of PD-L1 antibody in triple-negative breast cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.115004_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102258","article-title":"Nanofluidic delivery implant sustains localization and maximizes efficacy of intratumoral immunotherapy","volume":"56","author":"Liu","year":"2024","journal-title":"Nano Today"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115004_bb0145","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1021\/acscentsci.3c01310","article-title":"Mannosylated STING agonist drugamers for dendritic cell-mediated cancer immunotherapy","volume":"10","author":"Nguyen","year":"2024","journal-title":"ACS Cent. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115004_bb0150","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","article-title":"cGAS-STING pathway in cancer biotherapy","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115004_bb0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu. Rev. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115004_bb0160","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10895-008-0357-7","article-title":"Diffusion coefficients of several rhodamine derivatives as determined by pulsed field gradient\u2013nuclear magnetic resonance and fluorescence correlation spectroscopy","volume":"18","author":"Gendron","year":"2008","journal-title":"J. Fluoresc."},{"key":"10.1016\/j.jconrel.2026.115004_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfoodeng.2020.110400","article-title":"Predicting the performance of direct contact membrane distillation (DCMD): mathematical determination of appropriate tortuosity based on porosity","volume":"294","author":"Kim","year":"2021","journal-title":"J. Food Eng."},{"issue":"22","key":"10.1016\/j.jconrel.2026.115004_bb0170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.120638","article-title":"A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1\u2013insensitive models of triple-negative breast cancer","volume":"3","author":"Cheng","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jconrel.2026.115004_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.104300","article-title":"The development of 5-fluorouracil biodegradable implants: a comparative study of PCL\/PLGA blends","volume":"81","author":"Youssef","year":"2023","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115004_bb0180","doi-asserted-by":"crossref","DOI":"10.1002\/admt.202100410","article-title":"Developments of advanced electrospinning techniques: a critical review","volume":"6","author":"Li","year":"2021","journal-title":"Adv. Mater. Technol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115004_bb0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2011.09.064","article-title":"Poly-\u0454-caprolactone based formulations for drug delivery and tissue engineering: a review","volume":"158","author":"Dash","year":"2012","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115004_bb0190","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s13346-022-01177-8","article-title":"In vitro degradation and erosion behavior of commercial PLGAs used for controlled drug delivery","volume":"13","author":"Walker","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115004_bb0195","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/09553002.2019.1623429","article-title":"Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality","volume":"95","author":"Ko","year":"2019","journal-title":"Int. J. Radiat. Biol."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2026.115004_bb0200","first-page":"221","article-title":"Radiotherapy of breast cancer","volume":"26","author":"Hennequin","year":"2022","journal-title":"Cancer Radiother J Soc Francaise Radiother Oncol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926004074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:00:25Z","timestamp":1783051225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926004074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":40,"alternative-id":["S0168365926004074"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115004","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biodegradable nanofibrous drug-eluting seed for sustained intratumoral immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115004"}}